203 related articles for article (PubMed ID: 9395230)
61. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
62. Barrett's Esophagus and esophageal adenocarcinoma.
Bresalier RS
Annu Rev Med; 2009; 60():221-31. PubMed ID: 18783330
[TBL] [Abstract][Full Text] [Related]
63. Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice.
Hao J; Liu B; Yang CS; Chen X
BMC Gastroenterol; 2009 Jul; 9():59. PubMed ID: 19627616
[TBL] [Abstract][Full Text] [Related]
64. Role of obesity in Barrett's esophagus and cancer.
Murray L; Romero Y
Surg Oncol Clin N Am; 2009 Jul; 18(3):439-52. PubMed ID: 19500735
[TBL] [Abstract][Full Text] [Related]
65. Chemoprevention of carcinogenic progression to esophageal adenocarcinoma by the manganese superoxide dismutase supplementation.
Martin RC; Liu Q; Wo JM; Ray MB; Li Y
Clin Cancer Res; 2007 Sep; 13(17):5176-82. PubMed ID: 17785574
[TBL] [Abstract][Full Text] [Related]
66. Alteration of Esophageal Microbiome by Antibiotic Treatment Does Not Affect Incidence of Rat Esophageal Adenocarcinoma.
Sawada A; Fujiwara Y; Nagami Y; Tanaka F; Yamagami H; Tanigawa T; Shiba M; Tominaga K; Watanabe T; Gi M; Wanibuchi H; Arakawa T
Dig Dis Sci; 2016 Nov; 61(11):3161-3168. PubMed ID: 27461059
[TBL] [Abstract][Full Text] [Related]
67. IL-1β transgenic mouse model of inflammation driven esophageal and oral squamous cell carcinoma.
Muthupalani S; Annamalai D; Feng Y; Ganesan SM; Ge Z; Whary MT; Nakagawa H; Rustgi AK; Wang TC; Fox JG
Sci Rep; 2023 Aug; 13(1):12732. PubMed ID: 37543673
[TBL] [Abstract][Full Text] [Related]
68. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
[TBL] [Abstract][Full Text] [Related]
69. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
Thota PN; Vennalaganti P; Vennelaganti S; Young P; Gaddam S; Gupta N; Lieberman D; Sampliner R; Falk GW; Mathur S; Kennedy K; Cash BD; Moawad F; Bansal A; Spaander MC; Bruno MJ; Vargo J; Sharma P
Gastroenterology; 2017 Apr; 152(5):987-992. PubMed ID: 27988383
[TBL] [Abstract][Full Text] [Related]
70. Risk factors in the development of esophageal adenocarcinoma.
Pohl H; Wrobel K; Bojarski C; Voderholzer W; Sonnenberg A; Rösch T; Baumgart DC
Am J Gastroenterol; 2013 Feb; 108(2):200-7. PubMed ID: 23247577
[TBL] [Abstract][Full Text] [Related]
71. [Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide].
Oyama K; Fujimura T; Ninomiya I; Miyashita T; Kinami S; Fushida S; Ohta T
Nihon Shokakibyo Gakkai Zasshi; 2007 Aug; 104(8):1183-91. PubMed ID: 17675820
[TBL] [Abstract][Full Text] [Related]
72. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
[TBL] [Abstract][Full Text] [Related]
73. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
74. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
75. [Clinical outline of Barrett's esophagus].
Kuwano H; Sohda M; Kato H; Miyazaki T; Kimura H
Nihon Rinsho; 2005 Aug; 63(8):1372-8. PubMed ID: 16101224
[TBL] [Abstract][Full Text] [Related]
76. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
77. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
78. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen.
Fein M; Peters JH; Chandrasoma P; Ireland AP; Oberg S; Ritter MP; Bremner CG; Hagen JA; DeMeester TR
J Gastrointest Surg; 1998; 2(3):260-8. PubMed ID: 9841983
[TBL] [Abstract][Full Text] [Related]
79. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin.
Chen X; Li N; Wang S; Wu N; Hong J; Jiao X; Krasna MJ; Beer DG; Yang CS
J Natl Cancer Inst; 2003 Jul; 95(14):1053-61. PubMed ID: 12865451
[TBL] [Abstract][Full Text] [Related]
80. Studies on experimental animals involving surgical procedures and/or nitrosamine treatment related to the etiology of esophageal adenocarcinoma.
Mirvish SS
Cancer Lett; 1997 Aug; 117(2):161-74. PubMed ID: 9377544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
